Table 1.
Characteristics of patients and healthy volunteers (HVs).
| Group | Gender F/M |
Age (years) Mean ± SD |
Disease duration (years)** Mean ± SD |
EDSS** Mean ± SD |
EDSS before Nat. treatment Mean ± SD |
Annualized relapse rate during last 3 years Mean ± SD |
Annualized relapse rate on Nat. treatment Mean ± SD |
Number of relapse free patients on Nat. treatment |
|---|---|---|---|---|---|---|---|---|
| HV (n = 14) | 10/4 | 39.6 ± 10.1 | na | na | na | na | na | na |
| Untreated (n = 14) | 10/4 | 46.9 ± 9.4* | 9.64 ± 5.77 | 2.07 ± 1.08 | na | 0.45 ± 0.82 | na | na |
| Nat. treated (n = 14) | 10/4 | 39.4 ± 8.9 | 8.42 ± 4.83 | 3.03 ± 1.51 | 3.53 ± 1.39 | 0.83 ± 0.44*** | 0.35 ± 0.40 | 6/14 |
na: not applicable.
*Untreated RRMS patients are older than HVs (n.s.) and natalizumab (Nat.) treated patients (P < 0.05).
**At the sampling time.
***Before natalizumab (Nat.) treatment.